Next Article in Journal
Impact of STAS on Lung Resections for Adenocarcinoma: A Retrospective Analysis
Next Article in Special Issue
Robotic Gastrectomy and Delivery of Adjuvant Systemic Therapy in Locally Advanced Gastric Adenocarcinoma: An NCDB Propensity Score-Matched Analysis
Previous Article in Journal
Socioeconomic Factors Associated with Receipt of Minimally Invasive Surgery for NSCLC: Evidence from the National Cancer Database
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 18
Issue 4
10.3390/cancers18040602
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Outcomes After Robot-Assisted Versus Open Pancreatoduodenectomy: A Propensity Score-Matching Analysis in a High-Volume Center (TAKUMI-7)

by
Kosei Takagi
1,*,
Tomokazu Fuji
1,
Kazuya Yasui
1,
Yuzo Umeda
2,
Ryuichi Yoshida
1,
Motohiko Yamada
1,
Takeyoshi Nishiyama
1,
Yasuo Nagai
1,
Atene Ito
1,
Naohiro Okada
1,
Shohei Yokoyama
1 and
Toshiyoshi Fujiwara
1
1
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, Japan
2
Department of Hepatobiliary Pancreatic Surgery, Ehime University Graduate School of Medicine, Toon City 791-0295, Ehime, Japan
*
Author to whom correspondence should be addressed.
Cancers 2026, 18(4), 602; https://doi.org/10.3390/cancers18040602
Submission received: 21 January 2026 / Revised: 10 February 2026 / Accepted: 11 February 2026 / Published: 12 February 2026
(This article belongs to the Special Issue Laparoscopic and Robotic Surgery for Gastrointestinal and Hepato-Pancreato-Biliary Cancers)
Browse Figure
Review Reports Versions Notes

Simple Summary

The advantages of robot-assisted pancreatoduodenectomy (RPD) over open pancreatoduodenectomy (OPD) are currently unknown. In this study of 400 patients (162 with RPD and 238 with OPD), outcomes were compared using propensity score-matching (PSM) analysis. RPD demonstrated superior outcomes, including higher textbook outcome (TO) achievement rates before and after PSM. Moreover, robotic surgery was found to be significantly associated with TO after pancreatoduodenectomy. These results highlight the potential superiority of RPD over OPD in terms of short-term outcomes. Further investigation is warranted to confirm the potential long-term benefits of robotic surgeries.

Abstract

Background/Objectives: Although the safety and feasibility of robot-assisted pancreatoduodenectomy (RPD) compared to open pancreatoduodenectomy (OPD) have been reported, studies investigating the advantages of RPD remain limited. Moreover, only a few studies have investigated the effects of robotic surgery on textbook outcomes (TO). Methods: This single-center retrospective study included 400 patients who underwent RPD and OPD at our institution between January 2017 and December 2025. Outcomes were compared between the RPD (n = 162) and OPD (n = 238) groups using propensity score-matching (PSM) analysis. The factors associated with TO were examined. Results: Before PSM, significant differences were observed between the groups. PSM yielded RPD (n = 117) and OPD (n = 117) with equal preoperative factors. The RPD group demonstrated a significantly shorter operative time (402 vs. 444 min, p < 0.001), lesser blood loss (75 vs. 270 mL, p < 0.001), shorter postoperative hospital stays (13 vs. 22 days, p < 0.001), and fewer major complications (17.1 vs. 44.4%, p < 0.001), resulting in a higher TO achievement rate (76.9 vs. 52.1%, p = 0.001). Adjusted multivariate analyses identified robotic surgery (odds ratio 3.04, p < 0.001) as an independent predictor of TO. Conclusions: This study demonstrated that RPD was potentially superior to OPD in terms of short-term outcomes. Robotic surgery was significantly associated with TO after pancreatoduodenectomy at the expert’s hand.

1. Introduction

Pancreatoduodenectomy (PD) is the most commonly performed surgical procedure for resectable periampullary tumors [1]. Despite advances in surgical techniques and centralization of pancreatic surgery, postoperative morbidity remains high, with complication rates of approximately 40% and mortality rates below 5% [2,3,4]. Currently, robot-assisted PD (RPD) has been increasingly adopted to overcome the technical concerns associated with the laparoscopic approach [5,6]. Moreover, previous studies have reported the safety and feasibility of RPD compared to open PD (OPD) in high-volume centers worldwide [7,8]. However, RPD remains technically challenging and requires advanced surgical skills and knowledge of pancreatic surgery. Further evidence would help to elucidate the advantages of RPD over OPD [9].
Previous studies have focused on short-term outcomes, comparative outcomes of minimally invasive and open approaches, learning curves, and technical proficiency of RPD [10]. Among the various outcomes, the textbook outcome (TO) has been developed as a multidimensional metric for assessing the quality of pancreatic surgery [11]. However, few studies have investigated the outcomes of RPD versus OPD, focusing on TO in benign, premalignant, and malignant diseases.
This study aimed to investigate the safety and feasibility of RPD compared to OPD using propensity score-matching (PSM) analysis, as well as identify factors associated with TO, under the Training program at Okayama University for minimally invasive surgery (TAKUMI-7).

2. Materials and Methods

2.1. Study Design

This single-center retrospective study included 400 consecutive patients who underwent RPD or OPD at our institution between January 2017 and December 2025. The study was approved by the ethics committee of our institution (approval no. 2110-002) and was conducted in accordance with the Declaration of Helsinki. The need for informed consent was waived due to the retrospective nature of this study.

2.2. Data Collection

The following data were extracted from a prospectively maintained database: sex, age, body mass index (BMI), American Society of Anesthesiologists (ASA) physical status, comorbidities, preoperative biliary drainage, neoadjuvant chemotherapy, laboratory values, primary disease, operative variables (surgical approach, operative time, blood loss, surgeon type, conversion, and vascular reconstruction), pancreatic texture, main pancreatic duct diameter, and postoperative outcomes. Surgeons were divided into board-certified experts and surgical trainees [12]. Postoperative outcomes included length of postoperative hospital stay, mortality, reoperation, major complications [13], clinically relevant postoperative pancreatic fistula (CR-POPF) [14], post-pancreatectomy hemorrhage (PPH), bile leakage [15], and readmission within 1 month after surgery.

2.3. Definition of Postoperative Complications

Data on postoperative complications occurring within 1 month of surgery were recorded. Major complications were defined as grade ≥ 3 using the Clavien–Dindo classification [13]. Clinically relevant POPF (≥grade B) was evaluated using the International Study Group definition [14]. The conventional TO criteria for pancreatectomy include the absence of mortality, major complications, POPF, post-pancreatectomy hemorrhage, bile leakage, and readmission within one month after surgery [11].

2.4. Surgical Protocol and Selection Criteria

Surgical protocols for RPD and OPD have been described in previous publications [16,17,18]. The standard reconstruction for RPD and OPD was performed using the modified Child method [19], including pancreaticojejunostomy with the modified Blumgart method, hepaticojejunostomy, and gastrojejunostomy. For pancreaticojejunostomy anastomosis, a lost stent was placed in the RPD, and a lost or externalized stent was placed during the OPD, depending on the pancreatic duct diameter.
The concept of an enhanced recovery after surgery was first introduced in 2014 [20]. Perioperative care using an enhanced recovery after surgery protocol has been standardized for RPD and OPD. Drain management was identical between the RPD and OPD groups; drain removal was attempted after postoperative day 5 in patients with no bacterial contamination and clear drainage fluid.
RPD was introduced at our institution after officially being covered by the Japanese National Health Insurance in 2020. Our RPD protocol using the two-surgeon technique was standardized according to the Dutch Training Program (LAELAPS-3) in collaboration with the University of Pittsburgh Medical Center [21,22]. A robotic platform with a da Vinci Si or Xi system (Intuitive Surgical, Sunnyvale, CA, USA) was used.
RPD was indicated in selected patients with benign, premalignant, or malignant diseases. As RPD with vascular or other organ resection is not officially allowed by the Japanese National Health Insurance system, advanced tumors requiring vascular or other organ resection are indicated for OPD. Indications for the surgical approach were determined by a multidisciplinary team.

2.5. Statistical Analysis

Patient characteristics and outcomes stratified by the surgical approach were investigated. PSM analysis was performed using a logistic regression model to reduce selection bias based on potential confounding variables, including preoperative biliary drainage, neoadjuvant chemotherapy, primary disease, vascular reconstruction, and pancreatic texture. The propensity score was used for 1:1 matching with a caliper width of 0.20. Subsequently, univariate and multivariate logistic regression analyses were performed to identify the predictors of TO. Odds ratios (ORs) and 95% confidence intervals (CIs) were also determined. Values are presented as proportions for categorical data and medians (interquartile ranges [IQRs]) for continuous variables. All statistical analyses were performed using JMP software version 11 (SAS Institute, Cary, NC, USA).

3. Results

3.1. Implementation of RPD

The number of OPD and RPD conducted at our institution annually is shown in Figure 1a. Following their introduction in 2020, the number of RPDs increased steadily over time, from 11.4% in 2020 to 41.7% in 2021 and reaching 81.5% by 2025 (Figure 1b).

3.2. Patient Characteristics

Table 1 shows the baseline characteristics of the 400 patients. The cohort included 229 men and 171 women with a median age of 72 years (IQR, 64–77 years). Preoperative biliary drainage and neoadjuvant chemotherapy were administered in 157 and 126 patients, respectively. The laboratory values were within normal limits. The most common diagnoses were pancreatic cancer (n = 184, 46.0%) and benign tumors (n = 86, 21.5%). The cohort included 162 patients with RPD and 238 patients with OPD.
The patient characteristics regarding RPD and OPD before and after PSM are shown in Table 1. Significant differences were observed between the groups in terms of preoperative biliary drainage (p < 0.001), neoadjuvant chemotherapy (p < 0.001), and primary disease (p < 0.001) before PSM. After PSM, the preoperative characteristics of RPD were similar to those of OPD. In the PSM cohort, the area under the curve calculated from the receiver-operating characteristic curve was 0.787.

3.3. Outcomes of RPD Versus OPD

The overall outcomes are summarized in Table 2. The median operative time was 425 min (IQR: 378–489 min), with an estimated blood loss of 183 mL (IQR: 71–390 mL). Vascular reconstruction was performed in 78 (19.5%) patients. Of the 400 procedures, 330 were performed by board-certified surgeons and 70 by surgical trainees. The median postoperative hospital stay was 18 days (IQR, 13–24 days). The postoperative complications included mortality (n = 0, 0%), reoperation (n = 15, 3.8%), major complications (n = 128, 32.0%), CR-POPF (n = 60, 15.0%), PPH (n = 13, 3.3%), bile leakage (n = 11, 2.8%), and readmission (n = 28, 7.0%). TO was achieved in 255 (63.8%) patients. The reasons for reoperation included ileus (n = 3), delayed gastric emptying (n = 3), anastomotic leakage (n = 3), hematoma (n = 2), bile leakage (n = 1), wound dehiscence (n = 1), and others (n = 2). Further details on the nature of the major complications and CR-POPF included: major complications of grades 3a (n = 110), 3b (n = 14), and 4 (n = 4); CR-POPF of grades B (n = 58) and C (n = 2). The causes of readmission were surgical site infection (n = 6), cholangitis (n = 5), delayed gastric emptying (n = 4), PPH (n = 3), loss of appetite (n = 3), ascites (n = 2), enteritis (n = 2), ileus (n = 1), pneumonia (n = 1), and pancreatitis (n = 1).
The RPD and OPD outcomes before and after PSM are presented in Table 2. Before PSM, the RPD group had significantly shorter operative times and reduced blood loss. However, vascular reconstruction and pancreatic texture differed significantly between the groups.
In the PSM cohort, these differences were adjusted for equally. RPD was associated with a significantly shorter operative time (402 vs. 444 min, p < 0.001) and reduced blood loss (75 vs. 270 mL, p < 0.001). The RPD group had superior postoperative outcomes in terms of the length of the postoperative hospital stay (13 vs. 22 days, p < 0.001), major complications (17.1 vs. 44.4%, p < 0.001), and POPF (2.6 vs. 28.2%, p < 0.001), resulting in higher TO achievement (76.9 vs. 52.1%, p = 0.001).

3.4. Predictive Factors for TO

Table 3 shows the results of the univariate and multivariate analyses to identify the perioperative predictors associated with TO achievement. In univariate analyses, four variables were identified as independent factors: sex, BMI, pancreatic texture, and surgical approach. The unadjusted multivariate analyses revealed that a lower BMI (OR 2.18, 95% CI 1.23–3.86, p = 0.008), hard pancreas (OR 2.00, 95% CI 1.23–3.28, p = 0.005), and robotic surgery (OR 2.86, 95% CI 1.77–4.70, p < 0.001) were significantly associated with achievement of TO. After adjustment for perioperative factors, hard pancreas (OR 2.05, 95% CI 1.06–4.12, p = 0.034) and robotic surgery (OR 3.04, 95% CI 1.73–5.48, p < 0.001) were identified as independent predictors for achieving TO.

3.5. Outcomes of RPD Compared to Benchmark Study

Benchmark studies that have reported the outcomes of RPD are summarized in Table 4 [22,23,24,25,26,27]. Our results were comparable to those of published benchmarks, with equal surgical outcomes and a lower incidence of postoperative complications.

4. Discussion

The present study investigated the safety and feasibility of RPD compared with OPD in a high-volume center in Japan, including 162 RPDs and 238 OPDs, using PSM analysis. These results highlight the superiority of RPD, with significantly better short-term outcomes observed both before and after PSM. We evaluated the effects of robotic surgery on TO in patients with PD and found that robotic surgery was an independent predictor of TO after PD.
The implementation of RPD has been officially covered by the Japanese National Health Insurance since April 2020. Structured training programs, simulation training, mentorship, and centralization in high-volume centers are essential for optimizing surgical outcomes and ensuring patient safety [28]. Moreover, the median learning curve achievement point for RPD has been reported to be 36.5 cases (range: 20–80) [29]. As our surgical team participated in a nationwide training program for RPD in the Netherlands (LAELAPS-3) before the introduction of the RPD program at our institution [21,22], the influence of individual learning curves on surgical outcomes may have been limited. However, surgeons’ experience and learning curves are critical determinants of postoperative outcomes after pancreatectomy. As shown in Table 2, the RPDs were performed by only board-certified surgeons, mainly by a proctor (KT). By contrast, surgical trainees are involved in OPDs by proctoring board-certified surgeons. However, their first case was not included in the present study.
As the indications for RPD have gradually expanded over time from benign and premalignant tumors to malignant diseases, the proportion of RPD increased from 11.4% in 2020 to 81.5% in 2025 (Figure 1). Consequently, significant differences between the RPD and OPD groups were observed owing to different patient selection criteria (Table 1). Therefore, PSM was performed to balance the differences between the groups. All significant differences disappeared after PSM, with acceptable discrimination. CR-POPF is a major complication of PD, and soft pancreatic texture and small main pancreatic duct are known risk factors for POPF [30]. Because the preoperative evaluation of the pancreatic texture is difficult, this study included preoperative and intraoperative findings as matching variables. We considered that PSM using only preoperative variables, without adjusting for intraoperative variables, may mislead the interpretation of the results.
Recent meta-analyses comparing RPD and OPD demonstrated the potential advantages of RPD in terms of blood loss and postoperative outcomes, similar oncological outcomes, and the disadvantage of RPD with longer operative times [31,32]. In the present study, we found that the RPD group had superior outcomes compared to the OPD group before and after PSM, including a shorter operative time, reduced blood loss, lower incidence of complications, and shorter postoperative hospital stays, leading to a higher TO achievement rate (Table 2). Collectively, our results suggest the potential superiority of RPD over OPD with respect to short-term outcomes.
The TO rates for RPD in our study were higher than those reported in previous studies [22,33]. Structured surgical training through LAELAPS-3 likely facilitated the safe introduction of RPD at our center, which may have been associated with the higher TO rates [17]. Moreover, pancreatic texture and robotic surgery were independent predictors of TO (Table 3). To date, preoperative biliary drainage, tumor characteristics, soft pancreatic texture, small pancreatic duct, and increased blood loss have been reported as risk factors for failure to achieve TO after PD [34]. Our novel finding was that robotic surgery was associated with TO after PD. As TO achievement significantly improves survival in pancreatic cancer [35,36], robotic surgery with a higher TO achievement may contribute to improved postoperative prognosis following PD.
Although the same POPF mitigation strategies were used for RPD and OPD, the incidence of CR-POPF after RPD was notably lower in this study than in the OPD cohort and the benchmark studies cited in Table 4. Based on our previous study investigating the impact of robotic surgery on POPF in high-risk pancreaticojejunostomy, the lower incidence of CR-POPF after RPD may be attributed to precise anastomosis using the robotic platform and dedicated surgical performance [37]. Moreover, a lower drain discharge volume and incidence of positive drain fluid cultures after RPD may have led to a lower incidence of CR-POPF. In fact, a large drain volume and a high incidence of positive drain culture after OPD may cause longer drain retention, resulting in the development of CR-POPF [37].
This study has several limitations. First, this was a single-center, retrospective study with a relatively small sample size. Second, because the surgical indications for RPD and OPD differ, there may be a potential selection bias for robotic or open surgery. Although PSM analysis was performed to reduce these differences, other confounding factors may exist. Since the enrollment periods for the RPD and OPD groups were not synchronized, a chronological bias may exist. As the RPD group had a significantly later start date, this study may have exhibited a substantial selection bias. However, perioperative care has been standardized according to the enhanced recovery after surgery protocol since 2014. Therefore, it is unlikely that the institutional developments in perioperative care and the learning effects over the past three years have favored the RPD cohort in this study. Another limitation is the substantially higher proportion of procedures performed by surgical trainees in the OPD group compared to the RPD group. This imbalance may result in favorable postoperative outcomes for robotic surgery and represent a major cofounder. Finally, this study focused on the short-term outcomes of RPD and OPD, and the effect of robotic surgery on disease-specific long-term outcomes was not investigated. Similar oncological and survival outcomes have been reported between RPDs and OPDs for pancreatic cancer [26]. However, the effect of robotic surgery on long-term outcomes warrants further investigation in future studies.

5. Conclusions

This study demonstrated that RPD was potentially superior to OPD with regards to short-term outcomes. Robotic surgery was significantly associated with achieving TO following PD at the expert’s hand. Further studies will need to be conducted to demonstrate the potential benefits of robotic surgery in terms of long-term outcomes.

Author Contributions

Conceptualization, K.T.; Methodology, K.T.; Formal analysis, K.T.; Investigation, K.T., Resources, K.T., T.F. (Tomokazu Fuji), K.Y., Y.U., R.Y., M.Y., T.N., Y.N., A.I., N.O. and S.Y.; Writing—original draft, K.T.; Project administration, K.T.; Writing—review & editing. T.F. (Toshiyoshi Fujiwara); Supervision, T.F. (Toshiyoshi Fujiwara). All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was approved by the ethics committee of our institution (date of approval, 24 September 2021; approval no. 2110-002) and conducted in accordance with the Declaration of Helsinki.

Informed Consent Statement

The need for informed consent was waived due to the retrospective nature of the study.

Data Availability Statement

The original contributions of this study are included in this article. Further inquiries can be directed to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
RPDRobot-assisted pancreatoduodenectomy
OPDOpen pancreatoduodenectomy
PDPancreatoduodenectomy
TOTextbook outcome
PSMPropensity score matching
BMIBody mass index
ASAAmerican Society of Anesthesiologists
ASTAspartate aminotransferase
ALTAlanine aminotransferase
CR-POPFClinically relevant postoperative pancreatic fistula
PPHPost-pancreatectomy hemorrhage
CIConfidence interval
OROdds ratio
MPDMain pancreatic duct

References

  1. Whipple, A.O.; Parsons, W.B.; Mullins, C.R. Treatment of Carcinoma of the Ampulla of Vater. Ann. Surg. 1935, 102, 763–779. [Google Scholar] [CrossRef]
  2. Kimura, W.; Miyata, H.; Gotoh, M.; Hirai, I.; Kenjo, A.; Kitagawa, Y.; Shimada, M.; Baba, H.; Tomita, N.; Nakagoe, T.; et al. A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system: The 30-day and in-hospital mortality rates for pancreaticoduodenectomy. Ann. Surg. 2014, 259, 773–780. [Google Scholar] [CrossRef]
  3. Cameron, J.L.; He, J. Two thousand consecutive pancreaticoduodenectomies. J. Am. Coll. Surg. 2015, 220, 530–536. [Google Scholar] [CrossRef]
  4. Lefor, A.K. Robotic and laparoscopic surgery of the pancreas: An historical review. BMC Biomed. Eng. 2019, 1, 2. [Google Scholar] [CrossRef]
  5. Asbun, H.J.; Moekotte, A.L.; Vissers, F.L.; Kunzler, F.; Cipriani, F.; Alseidi, A.; D’Angelica, M.I.; Balduzzi, A.; Bassi, C.; Björnsson, B.; et al. The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection. Ann. Surg. 2020, 271, 1–14. [Google Scholar] [CrossRef] [PubMed]
  6. Abu Hilal, M.; van Ramshorst, T.M.E.; Boggi, U.; Dokmak, S.; Edwin, B.; Keck, T.; Khatkov, I.; Ahmad, J.; Al Saati, H.; Alseidi, A.; et al. The Brescia Internationally Validated European Guidelines on Minimally Invasive Pancreatic Surgery (EGUMIPS). Ann. Surg. 2024, 279, 45–57. [Google Scholar] [CrossRef] [PubMed]
  7. Zhang, W.; Huang, Z.; Zhang, J.; Che, X. Safety and efficacy of robot-assisted versus open pancreaticoduodenectomy: A meta-analysis of multiple worldwide centers. Updates Surg. 2021, 73, 893–907. [Google Scholar] [CrossRef]
  8. Zhao, W.; Liu, C.; Li, S.; Geng, D.; Feng, Y.; Sun, M. Safety and efficacy for robot-assisted versus open pancreaticoduodenectomy and distal pancreatectomy: A systematic review and meta-analysis. Surg. Oncol. 2018, 27, 468–478. [Google Scholar] [CrossRef]
  9. Uijterwijk, B.A.; Wei, K.; Kasai, M.; Ielpo, B.; Hilst, J.V.; Chinnusamy, P.; Lemmers, D.H.L.; Burdio, F.; Senthilnathan, P.; Besselink, M.G.; et al. Minimally invasive versus open pancreatoduodenectomy for pancreatic ductal adenocarcinoma: Individual patient data meta-analysis of randomized trials. Eur. J. Surg. Oncol. 2023, 49, 1351–1361. [Google Scholar] [CrossRef]
  10. Abdelwahab, S.I.; Taha, M.M.E.; Farasani, A.; Moshi, J.M.; Assiri, A.; Alshahrani, S.; Sahli, K.A.; Shubaily, H.M.; Qadri, M.; Khardali, A.; et al. Robot-assisted pancreaticoduodenectomy: A bibliometric analysis of trends, key contributors, and collaborations. J. Robot. Surg. 2025, 20, 91. [Google Scholar] [CrossRef] [PubMed]
  11. van Roessel, S.; Mackay, T.M.; van Dieren, S.; van der Schelling, G.P.; Nieuwenhuijs, V.B.; Bosscha, K.; van der Harst, E.; van Dam, R.M.; Liem, M.S.L.; Festen, S.; et al. Textbook Outcome: Nationwide Analysis of a Novel Quality Measure in Pancreatic Surgery. Ann. Surg. 2020, 271, 155–162. [Google Scholar] [CrossRef]
  12. Otsubo, T.; Kobayashi, S.; Sano, K.; Misawa, T.; Ota, T.; Katagiri, S.; Yanaga, K.; Yamaue, H.; Kokudo, N.; Unno, M.; et al. Safety-related outcomes of the Japanese Society of Hepato-Biliary-Pancreatic Surgery board certification system for expert surgeons. J. Hepatobiliary Pancreat. Sci. 2017, 24, 252–261. [Google Scholar] [CrossRef] [PubMed]
  13. Clavien, P.A.; Barkun, J.; de Oliveira, M.L.; Vauthey, J.N.; Dindo, D.; Schulick, R.D.; de Santibañes, E.; Pekolj, J.; Slankamenac, K.; Bassi, C.; et al. The Clavien-Dindo classification of surgical complications: Five-year experience. Ann. Surg. 2009, 250, 187–196. [Google Scholar] [CrossRef] [PubMed]
  14. Bassi, C.; Marchegiani, G.; Dervenis, C.; Sarr, M.; Abu Hilal, M.; Adham, M.; Allen, P.; Andersson, R.; Asbun, H.J.; Besselink, M.G.; et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery 2017, 161, 584–591. [Google Scholar] [CrossRef]
  15. Koch, M.; Garden, O.J.; Padbury, R.; Rahbari, N.N.; Adam, R.; Capussotti, L.; Fan, S.T.; Yokoyama, Y.; Crawford, M.; Makuuchi, M.; et al. Bile leakage after hepatobiliary and pancreatic surgery: A definition and grading of severity by the International Study Group of Liver Surgery. Surgery 2011, 149, 680–688. [Google Scholar] [CrossRef]
  16. Takagi, K.; Yoshida, R.; Yagi, T.; Umeda, Y.; Nobuoka, D.; Kuise, T.; Fujiwara, T. Radiographic sarcopenia predicts postoperative infectious complications in patients undergoing pancreaticoduodenectomy. BMC Surg. 2017, 17, 64. [Google Scholar] [CrossRef]
  17. Takagi, K.; Umeda, Y.; Yoshida, R.; Yagi, T.; Fujiwara, T.; Zureikat, A.H.; Hogg, M.E.; Koerkamp, B.G. Surgical training model and safe implementation of robotic pancreatoduodenectomy in Japan: A technical note. World J. Surg. Oncol. 2021, 19, 55. [Google Scholar] [CrossRef] [PubMed]
  18. Takagi, K.; Umeda, Y.; Yoshida, R.; Fuji, T.; Yasui, K.; Kimura, J.; Hata, N.; Mishima, K.; Yagi, T.; Fujiwara, T. Surgical Strategies to Dissect around the Superior Mesenteric Artery in Robotic Pancreatoduodenectomy. J. Clin. Med. 2022, 11, 7112. [Google Scholar] [CrossRef]
  19. Child, C.G. Pancreaticojejunostomy and Other Problems Associated With the Surgical Management of Carcinoma Involving the Head of the Pancreas: Report of Five Additional Cases of Radical Pancreaticoduodenectomy. Ann. Surg. 1944, 119, 845–855. [Google Scholar] [CrossRef]
  20. Takagi, K.; Yoshida, R.; Yagi, T.; Umeda, Y.; Nobuoka, D.; Kuise, T.; Hinotsu, S.; Matsusaki, T.; Morimatsu, H.; Eguchi, J.; et al. Effect of an enhanced recovery after surgery protocol in patients undergoing pancreaticoduodenectomy: A randomized controlled trial. Clin. Nutr. 2019, 38, 174–181. [Google Scholar] [CrossRef]
  21. Zwart, M.J.W.; Nota, C.L.M.; de Rooij, T.; van Hilst, J.; Te Riele, W.W.; van Santvoort, H.C.; Hagendoorn, J.; Borei Rinkes, I.H.M.; van Dam, J.L.; Latenstein, A.E.J.; et al. Outcomes of a Multicenter Training Program in Robotic Pancreatoduodenectomy (LAELAPS-3). Ann. Surg. 2022, 276, e886–e895. [Google Scholar] [CrossRef]
  22. Zwart, M.J.W.; van den Broek, B.; de Graaf, N.; Suurmeijer, J.A.; Augustinus, S.; Te Riele, W.W.; van Santvoort, H.C.; Hagendoorn, J.; Borel Rinkes, I.H.M.; van Dam, J.L.; et al. The Feasibility, Proficiency, and Mastery Learning Curves in 635 Robotic Pancreatoduodenectomies Following a Multicenter Training Program: “Standing on the Shoulders of Giants”. Ann. Surg. 2023, 278, e1232–e1241. [Google Scholar] [CrossRef]
  23. Zureikat, A.H.; Beane, J.D.; Zenati, M.S.; Al Abbas, A.I.; Boone, B.A.; Moser, A.J.; Bartlett, D.L.; Hogg, M.E.; Zeh, H.J., 3rd. 500 Minimally Invasive Robotic Pancreatoduodenectomies: One Decade of Optimizing Performance. Ann. Surg. 2021, 273, 966–972. [Google Scholar] [CrossRef]
  24. Lee, M.; Chae, Y.S.; Park, S.; Yun, W.G.; Jung, H.S.; Han, Y.; Kwon, W.; Park, J.S.; Jang, J.Y. Current trends in types of pancreatoduodenectomy: Focus on the advancement of robot-assisted pancreatoduodenectomy with 630 consecutive cases. J. Hepatobiliary Pancreat. Sci. 2024, 32, 82–89. [Google Scholar] [CrossRef]
  25. Vining, C.C.; Kuchta, K.; Berger, Y.; Paterakos, P.; Schuitevoerder, D.; Roggin, K.K.; Talamonti, M.S.; Hogg, M.E. Robotic pancreaticoduodenectomy decreases the risk of clinically relevant post-operative pancreatic fistula: A propensity score matched NSQIP analysis. HPB 2021, 23, 367–378. [Google Scholar] [CrossRef]
  26. Liu, Q.; Zhao, Z.; Zhang, X.; Wang, W.; Han, B.; Chen, X.; Tan, X.; Xu, S.; Zhao, G.; Gao, Y.; et al. Perioperative and Oncological Outcomes of Robotic Versus Open Pancreaticoduodenectomy in Low-Risk Surgical Candidates: A Multicenter Propensity Score-Matched Study. Ann. Surg. 2023, 277, e864–e871. [Google Scholar] [CrossRef] [PubMed]
  27. Nakamura, S.; Nakata, K.; Nagakawa, Y.; Kozono, S.; Wakabayashi, G.; Wakabayashi, T.; Uyama, I.; Takahara, T.; Takeda, Y.; Ohmura, Y.; et al. The safety and feasibility of robotic pancreaticoduodenectomy: A multicenter retrospective assessment of 425 patients in Japan. J. Hepatobiliary Pancreat. Sci. 2025, 32, 124–131. [Google Scholar] [CrossRef] [PubMed]
  28. Caringi, S.; Delvecchio, A.; Casella, A.; De Palma, C.; Ferraro, V.; Filippo, R.; Stasi, M.; Tralli, N.; Manzia, T.M.; Memeo, R.; et al. Robotic Pancreaticoduodenectomy: Current Evidence and Future Perspectives. J. Clin. Med. 2025, 14, 8372. [Google Scholar] [CrossRef] [PubMed]
  29. Fung, G.; Sha, M.; Kunduzi, B.; Froghi, F.; Rehman, S.; Froghi, S. Learning curves in minimally invasive pancreatic surgery: A systematic review. Langenbeck’s Arch. Surg. 2022, 407, 2217–2232. [Google Scholar] [CrossRef]
  30. Schuh, F.; Mihaljevic, A.L.; Probst, P.; Trudeau, M.T.; Müller, P.C.; Marchegiani, G.; Besselink, M.G.; Uzunoglu, F.; Izbicki, J.R.; Falconi, M.; et al. A Simple Classification of Pancreatic Duct Size and Texture Predicts Postoperative Pancreatic Fistula: A classification of the International Study Group of Pancreatic Surgery. Ann. Surg. 2023, 277, e597–e608. [Google Scholar] [CrossRef]
  31. Fu, Y.; Qiu, J.; Yu, Y.; Wu, D.; Zhang, T. Meta-analysis of robotic versus open pancreaticoduodenectomy in all patients and pancreatic cancer patients. Front. Surg. 2022, 9, 989065. [Google Scholar] [CrossRef] [PubMed]
  32. Waseem, M.H.; Abideen, Z.U.; Durrani, R.; Dilawar, E.; Kamran, M.S.; Butt, H.T.; Khan, H.J.; Ahad, A.; Shakoor, P.; Jeswani, H.K.; et al. Comparing Operative Outcomes and Resection Quality in Robotic vs Open Pancreaticoduodenectomy: A Meta-analysis of 54,000 Patients. J. Gastrointest. Cancer 2025, 56, 57. [Google Scholar] [CrossRef]
  33. Lee, B.; Han, H.S.; Yoon, Y.S.; Lee, J.S. Textbook Outcomes of Totally Robotic Versus Totally Laparoscopic Pancreaticoduodenectomy for Periampullary Neoplasm: A Propensity Score-Matched Cohort Study. J. Clin. Med. 2025, 14, 6687. [Google Scholar] [CrossRef] [PubMed]
  34. Yuan, J.; Du, C.; Wu, H.; Zhong, T.; Zhai, Q.; Peng, J.; Liu, N.; Li, J. Risk factors of failure to achieve textbook outcome in patients after pancreatoduodenectomy: A systematic review and meta-analysis. Int. J. Surg. 2025, 111, 3093–3106. [Google Scholar] [CrossRef] [PubMed]
  35. Wang, H.; Hu, X.; Yin, C.; Zhou, D.; Li, Z.; Ma, Z.; Zhang, H. Association of textbook outcomes with improved survival in pancreatic ductal adenocarcinoma following pancreaticoduodenectomy: A retrospective study. Transl. Gastroenterol. Hepatol. 2024, 9, 38. [Google Scholar] [CrossRef]
  36. Yasui, K.; Takagi, K.; Fuji, T.; Nishiyama, T.; Nagai, Y.; Matsumoto, K.; Horiguchi, S.; Fujii, Y.; Otsuka, M.; Fujiwara, T. Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus S-1 in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Cancers 2025, 17, 3287. [Google Scholar] [CrossRef]
  37. Fuji, T.; Takagi, K.; Umeda, Y.; Yasui, K.; Yamada, M.; Nagai, Y.; Fujiwara, T. Impact of Robotic Surgery on Postoperative Pancreatic Fistula for High-Risk Pancreaticojejunostomy after Pancreatoduodenectomy. Dig. Surg. 2025, 42, 49–58. [Google Scholar] [CrossRef]
Cancers 18 00602 g001
Figure 1. (a) Trends in surgical approaches of pancreatoduodenectomy over time. (b) Proportion of surgical approaches to pancreatoduodenectomy over time. OPD, open pancreatoduodenectomy; RPD, robot-assisted pancreatoduodenectomy.
Figure 1. (a) Trends in surgical approaches of pancreatoduodenectomy over time. (b) Proportion of surgical approaches to pancreatoduodenectomy over time. OPD, open pancreatoduodenectomy; RPD, robot-assisted pancreatoduodenectomy.
Cancers 18 00602 g001
Table 1. Baseline characteristics stratified by surgical approaches: overall and propensity score-matching cohort.
Table 1. Baseline characteristics stratified by surgical approaches: overall and propensity score-matching cohort.
Before PSMAfter PSM
VariablesTotalRPDOPDp-ValueRPDOPDp-Value
No. of patients400162238 117117
Sex
Men229 (57.2)93 (57.4)136 (57.1)0.95868 (58.1)71 (60.7)0.690
Women171 (42.8)69 (42.6)102 (42.9) 49 (41.9)46 (39.3)
Age, years72 (64–77)72 (64–77)71 (64–77)0.93073 (66–77)71 (64–77)0.538
BMI, kg/m222.2 (20.3–24.1)22.1 (20.6–24.0)22.3 (20.2–24.2)0.67122.1 (20.6–23.6)22.7 (20.4–24.3)0.380
ASA score
1–2330 (82.5)131 (80.9)199 (83.6)0.47991 (77.8)99 (84.6)0.180
3–470 (17.5)31 (19.1)39 (16.4) 26 (22.2)18 (15.4)
Comorbidity
Hypertension165 (41.3)64 (39.5)101 (42.4)0.55948 (41.0)45 (38.5)0.689
Diabetes102 (25.5)41 (25.3)61 (25.6)0.94233 (28.2)29 (24.8)0.553
Preoperative biliary drainage157 (39.3)46 (28.4)111 (46.6)<0.00143 (36.8)47 (40.2)0.591
Neoadjuvant chemotherapy126 (31.5)26 (16.1)100 (42.0)<0.00125 (21.4)30 (25.6)0.441
Laboratory value
Total bilirubin, mg/dL0.6 (0.5–0.9)0.6 (0.5–0.8)0.6 (0.5–0.9) WNL0.6 (0.5–0.8)0.6 (0.5–0.9) WNL
Albumin, g/dL3.9 (3.6–4.2)4.0 (3.7–4.3)4.0 (3.6–4.2)WNL3.9 (3.6–4.2)3.9 (3.6–4.1)WNL
AST, U/L21 (17–28)20 (16–25)22 (18–31)WNL21 (17–28)24 (18–32)WNL
ALT, U/L19 (13–30)17 (12–26)20 (13–31)WNL17 (12–31)21 (15–35)WNL
Primary diseases
Pancreatic cancer184 (46.0)47 (29.0)137 (57.6)<0.00141 (35.0)49 (41.9)0.712
Bile duct cancer52 (13.0)24 (14.8)28 (11.8) 22 (18.8)22 (18.8)
Ampullary adenocarcinoma36 (9.0)14 (8.6)22 (9.2) 14 (12.0)13 (11.1)
Duodenal carcinoma21 (5.3)13 (8.0)8 (3.4) 11 (9.4)6 (5.1)
Benign tumors86 (21.5)60 (37.0)26 (10.9) 25 (21.4)25 (21.4)
Others21 (5.3)4 (2.5)17 (7.1) 4 (3.4)3 (1.7)
Values are reported as n (%) or medians (interquartile range). BMI, body mass index; ASA, American Society of Anesthesiologists; PSM, propensity score matching; RPD, robot-assisted pancreatoduodenectomy; OPD, open pancreatoduodenectomy; AST, aspartate aminotransferase; ALT, alanine aminotransferase; WNL, within normal limits.
Table 2. Outcomes stratified by surgical approaches: Overall and propensity score-matching cohort.
Table 2. Outcomes stratified by surgical approaches: Overall and propensity score-matching cohort.
Before PSMAfter PSM
VariablesTotalRPDOPDp-ValueRPDOPDp-Value
No. of patients400162238 117117
Operative factors
Operative time, min425 (378–489)403 (355–446)454 (396–511)<0.001402 (359–454)444 (393–500)<0.001
Blood loss, mL183 (71–390)75 (18–150)325 (150–510)<0.00175 (20–165)270 (130–445)<0.001
Surgeon type
Board-certified surgeon330 (82.5)162 (100)168 (70.6)<0.001117 (100)43 (36.8)<0.001
Surgical trainee70 (17.5)0 (0)70 (29.4) 0 (0)74 (63.2)
Conversion to open surgery55 (3.1)--5 (4.3)--
Vascular reconstruction78 (19.5)1 (0.6)77 (32.4)<0.0011 (0.9)1 (0.9)1.00
Pancreatic texture
Soft232 (58.0)122 (75.3)110 (46.2)<0.00179 (67.5)80 (68.4)0.915
Hard145 (36.3)36 (22.2)109 (45.8) 34 (29.1)32 (27.4)
Unavailable23 (5.7)4 (2.5)19 (8.0) 4 (3.4)5 (4.3)
MPD diameter, mm3 (2–5)3 (2–4)3 (2–5)0.0483 (2–4)3 (2–4)0.248
Postoperative factors
Postoperative hospital stay, days18 (13–24)13 (9–16)22 (17–29)<0.00113 (10–16)22 (18–30)<0.001
Mortality0 (0)0 (0)0 (0)-0 (0)0 (0)-
Reoperation15 (3.8)7 (4.3)8 (3.4)0.6224 (3.4)4 (3.4)1.00
Major complications128 (32.0)33 (20.4)95 (39.9)<0.00120 (17.1)52 (44.4)<0.001
Grade 3a110 (85.9)2684 1647
Grade 3b14 (10.9)68 44
Grade 44 (3.1)13 01
CR-POPF (≥grade B)60 (15.0)6 (3.7)54 (22.7)<0.0013 (2.6)33 (28.2)<0.001
Grade B58 (96.7)553 332
Grade C2 (3.3)11 01
PPH13 (3.3)3 (1.9)10 (4.2)0.182 (1.7)7 (6.0)0.08
Bile leakage11 (2.8)2 (1.2)9 (3.8)0.1072 (1.7)7 (6.0)0.081
Readmission28 (7.0)16 (9.9)12 (5.0)0.06612 (10.3)4 (3.4)0.034
Textbook outcome255 (63.8)122 (75.3)132 (55.9)<0.00190 (76.9)61 (52.1)0.001
Values are reported as n (%) or medians (interquartile range). MPD, main pancreatic duct; CR-POPF, clinically relevant postoperative pancreatic fistula; PPH, postpancreatectomy hemorrhage; PSM, propensity score matching; RPD, robot-assisted pancreatoduodenectomy; OPD, open pancreatoduodenectomy.
Table 3. Predictors associated with achievement of textbook outcomes.
Table 3. Predictors associated with achievement of textbook outcomes.
VariablesUnivariate AnalysisMultivariable Analysis
(Unadjusted)		Multivariable Analysis
(Adjusted)
OR95% CIp-ValueOR95% CIp-ValueOR95% CIp-Value
Age: ≥75 years (vs. <75)1.240.81–1.910.322
Sex: women (vs. men)1.561.03–2.390.0351.530.97–2.420.0671.410.79–2.580.248
BMI: <25 (vs. ≥25) 2.131.24–3.670.0062.181.23–3.860.0081.860.86–4.070.116
ASA: 1–2 (vs. 3–4)1.210.71–2.050.475
Preoperative biliary drainage: absence (vs. presence)1.380.91–2.090.132
Neoadjuvant chemotherapy: presence (vs. absence)1.270.82–1.990.293
Hypertension: absence (vs. presence)1.150.76–1.740.501
Diabetes: presence (vs. absence)1.510.94–2.480.093
Benign diseases (vs. malignant)1.510.93–2.500.093
Hard pancreas (vs. soft pancreas)1.581.02–2.480.0412.001.23–3.280.0052.051.06–4.120.034
Robotic surgery (vs. open surgery)2.411.56–3.76<0.0012.861.77–4.70<0.0013.041.73–5.48<0.001
BMI, body mass index; ASA, American Society of Anesthesiologists; OR, odds ratio; CI, confidence interval.
Table 4. A summary of studies reporting short-term outcomes of RPD.
Table 4. A summary of studies reporting short-term outcomes of RPD.
AuthorsOur StudyZwart et al. [22]Zureikat et al. [23]Lee et al. [24]Vining et al. [25]Liu et al. [26]Nakamura et al. [27]
Study designSingle-center (OUH)Multicenter
(LAELAPS-3)		Single-center (UPMC)Single-center (SNUH)MulticenterMulticenterMulticenter
CountryJapanThe NetherlandsUSARepublic of KoreaUSAChinaJapan
Year2026202320212024202120232025
Sample size1626355006304951032425
Operative time, min403 (355–446)395 (341−465)415 ± 107329  ±  81430 ± 122265 (240–304)617 (456–834) *
Blood loss, mL75 (18–150)200 (100–450)250 (150–400)493  ±  665-190 (150–240)160 (30–558) *
Conversion3.1%6.6%5.2%6.7%13.5%3.1%3.8%
CR-POPF3.7%26.9%7.8%10.6%11.9%10.2%22.1%
Bile leakage1.2%8.0%- -6.1%-
Postoperative hospital stay, days13 (9–16)11 (7–19)8 (6–11)11.2  ±  17.67 (6–9)12 (9–16)20 (12–41) *
Mortality0%3.5%3.0% (90 d)1.4% (90 d)1.6% (30 d)3.0% (90 d)0.5% (90 d)
Readmission9.9% (30 d)22.8% (30 d)35.5% (90 d)6.5% (30 d)24.2% (30 d)6.6% (90 d)-
Textbook outcome75.3%68.3%-----
Values are reported as median (interquartile range), * median with a range (10–90 percentile), or mean  ±  standard deviation. USA, United States of America; OUH, Okayama University Hospital; UPMC, University of Pittsburgh Medical Center; SNUH, Seoul National University Hospital; CR-POPF, clinically relevant postoperative pancreatic fistula.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Takagi, K.; Fuji, T.; Yasui, K.; Umeda, Y.; Yoshida, R.; Yamada, M.; Nishiyama, T.; Nagai, Y.; Ito, A.; Okada, N.; et al. Outcomes After Robot-Assisted Versus Open Pancreatoduodenectomy: A Propensity Score-Matching Analysis in a High-Volume Center (TAKUMI-7). Cancers 2026, 18, 602. https://doi.org/10.3390/cancers18040602

AMA Style

Takagi K, Fuji T, Yasui K, Umeda Y, Yoshida R, Yamada M, Nishiyama T, Nagai Y, Ito A, Okada N, et al. Outcomes After Robot-Assisted Versus Open Pancreatoduodenectomy: A Propensity Score-Matching Analysis in a High-Volume Center (TAKUMI-7). Cancers. 2026; 18(4):602. https://doi.org/10.3390/cancers18040602

Chicago/Turabian Style

Takagi, Kosei, Tomokazu Fuji, Kazuya Yasui, Yuzo Umeda, Ryuichi Yoshida, Motohiko Yamada, Takeyoshi Nishiyama, Yasuo Nagai, Atene Ito, Naohiro Okada, and et al. 2026. "Outcomes After Robot-Assisted Versus Open Pancreatoduodenectomy: A Propensity Score-Matching Analysis in a High-Volume Center (TAKUMI-7)" Cancers 18, no. 4: 602. https://doi.org/10.3390/cancers18040602

APA Style

Takagi, K., Fuji, T., Yasui, K., Umeda, Y., Yoshida, R., Yamada, M., Nishiyama, T., Nagai, Y., Ito, A., Okada, N., Yokoyama, S., & Fujiwara, T. (2026). Outcomes After Robot-Assisted Versus Open Pancreatoduodenectomy: A Propensity Score-Matching Analysis in a High-Volume Center (TAKUMI-7). Cancers, 18(4), 602. https://doi.org/10.3390/cancers18040602

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop